Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Current Assets (2020 - 2026)

PROCEPT BioRobotics has reported Current Assets over the past 7 years, most recently at $428.0 million for Q1 2026.

  • Quarterly Current Assets fell 8.11% to $428.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $428.0 million through Mar 2026, down 8.11% year-over-year, with the annual reading at $450.4 million for FY2025, 6.53% down from the prior year.
  • Current Assets was $428.0 million for Q1 2026 at PROCEPT BioRobotics, down from $450.4 million in the prior quarter.
  • Over five years, Current Assets peaked at $481.8 million in Q4 2024 and troughed at $230.0 million in Q2 2023.
  • The 5-year median for Current Assets is $329.2 million (2024), against an average of $357.4 million.
  • Year-over-year, Current Assets fell 22.9% in 2023 and then soared 42.3% in 2025.
  • A 5-year view of Current Assets shows it stood at $272.6 million in 2022, then grew by 28.59% to $350.6 million in 2023, then surged by 37.45% to $481.8 million in 2024, then fell by 6.53% to $450.4 million in 2025, then fell by 4.96% to $428.0 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Current Assets are $428.0 million (Q1 2026), $450.4 million (Q4 2025), and $454.8 million (Q3 2025).